Key histological markers include PD-L1 expression on tumor cells and immune cells, the presence of tumor-infiltrating lymphocytes (TILs), and the overall architecture of the tumor microenvironment. High levels of PD-L1 expression and a significant presence of TILs are generally associated with a better response to checkpoint inhibitor therapy.
